HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.

Abstract
Voriconazole is the first-line antifungal choice in the treatment of invasive fungal infections (IFIs). Single nucleotide polymorphisms (SNPs) in drug-metabolizing and transporter genes may affect voriconazole pharmacokinetics. This study aimed to determine the frequency of the CYP2C19 rs4244285, rs4986893, rs72552267, and rs12248560, CYP3A4 rs4646437, ABCB1 rs1045642, and FMO3 rs2266782 alleles and determine the association between these genetic variants and voriconazole concentrations in Thai patients with invasive fungal infections. The study comprised 177 Thai patients with IFIs in whom seven SNPs in CYP2C19, CYP3A4, ABCB1, and FMO3 were genotyped using TaqMan real-time polymerase chain reaction (RT-PCR) 5´ nuclease assays, and voriconazole plasma concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). Of the 177 patients included, 31 were <12 years and 146 were ≥12 years. The CYP2C19 allele frequencies were 0.29 for *2, 0.060 for *3, 0.003 for *6, and 0.008 for *17. The allele frequency of CYP3A4 (rs4646437) was 0.26, ABCB1 (rs1045642) was 0.36, and FMO3 (rs2266782) was 0.16. The median voriconazole dose/weight was significantly lower in patients aged ≥12 years when compared to the patients aged <12 years (P < .001). Patients aged <12 years with CYP2C19*1/*2 exhibited significantly higher median voriconazole plasma concentrations than those with the CYP2C19*1/*1 (P = .038). However, there were no significant differences in median voriconazole plasma concentrations among the CYP2C19 genotypes in the patients aged ≥12 years. There was a lack of association observed among the CYP3A4, ABCB1, and FMO3 genotypes on the plasma voriconazole concentrations in both groups of patients. Our findings indicate that voriconazole plasma concentrations are affected by the CYP2C19*2 allele in patients aged <12 years but not in patients aged ≥12 years.
AuthorsSumonrat Chuwongwattana, Thawinee Jantararoungtong, Santirat Prommas, Sadeep Medhasi, Apichaya Puangpetch, Chonlaphat Sukasem
JournalPharmacology research & perspectives (Pharmacol Res Perspect) Vol. 8 Issue 6 Pg. e00665 (12 2020) ISSN: 2052-1707 [Electronic] United States
PMID33124772 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Chemical References
  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • Antifungal Agents
  • Oxygenases
  • dimethylaniline monooxygenase (N-oxide forming)
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Voriconazole
Topics
  • ATP Binding Cassette Transporter, Subfamily B (genetics)
  • Adolescent
  • Adult
  • Aged
  • Antifungal Agents (blood, therapeutic use)
  • Child
  • Child, Preschool
  • Cytochrome P-450 CYP2C19 (genetics)
  • Cytochrome P-450 CYP3A (genetics)
  • Female
  • Genotype
  • Humans
  • Invasive Fungal Infections (blood, drug therapy, epidemiology, genetics)
  • Male
  • Middle Aged
  • Oxygenases (genetics)
  • Retrospective Studies
  • Thailand (epidemiology)
  • Voriconazole (blood, therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: